Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
02256 ABBISKO-B
3.250-0.090-2.69%
Closed
02/03 16:08 CCT
High
3.520
Open
3.340
Turnover
1.09M
Low
3.250
Pre Close
3.340
Volume
324.00K
Price Forecast
News
Comment
US FDA Grants Breakthrough Therapy Designation to Abbisko's Tumor Treatment
02:07 AM EST, 01/30/2023 (MT Newswires) -- The US Food and Drug Administration granted breakthrough therapy designation to Abbisko Cayman's (HKG:2256) CSF-1R inhibitor pimicotinib, a treatment for ten
Abbisko Cayman's Liver Cancer Treatment Well-Tolerated in Phase 1 Trial
10:23 PM EST, 12/14/2022 (MT Newswires) -- Abbisko Cayman's (HKG:2256) irpagratinib treatment for second-line hepatocellular carcinoma, or primary liver cancer, was well-tolerated in patients during a
Abbisko Cayman Unit's Bladder Cancer Treatment Well Tolerated in Chinese Patients in Phase II Trial
08:48 PM EST, 12/07/2022 (MT Newswires) -- Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics' fexagratinib treatment for urothelial, or bladder, carcinoma was well tolerated by Chinese patients duri
Abbisko to Publish Results of Tenosynovial Tumor Medication Phase 1B Trial at Meeting in Canada
01:31 AM EST, 11/15/2022 (MT Newswires) -- Abbisko (HKG:2256) will publish the results of its phase 1B study of the ABSK021 medication for tenosynovial giant cell tumor at the Connective Tissue Oncolo
Abbisko Enrolls First Patient in Phase 2 Clinical Trial for Bladder Cancer Combination Treatment
11:18 PM EDT, 11/03/2022 (MT Newswires) -- Abbisko Cayman (HKG:2256) completed the enrollment of the first patient in the phase 2 clinical trial of its ABSK091 inhibitor combined with the tieslelizuma
US FDA Approves Abbisko's Clinical Trial for Tumor Medication
Abbisko Cayman (HKG:2256) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring
China Approves Abbisko's Phase 3 Clinical Trial for Tumor Medication
11:08 PM EDT, 10/24/2022 (MT Newswires) -- China's medical products regulator approved Abbisko Cayman's (HKG:2256) phase 3 clinical trial for its ABSK021 anti-tumor medication, a Tuesday bourse filing
And reputation-interim report of BRV 2022
Abbisko Doses First Patient in China Clinical Trial of Cancer Drug
02:39 AM EDT, 09/27/2022 (MT Newswires) -- Abbisko (HKG:2256) subsidiary Abbisko Therapeutics dosed the first patient in its phase I clinical trial in China of ABSK043, an anti-cancer drug candidate,
Company Overview
More
We are an R&D-driven clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since inception, we have built a strong internal R&D engine, supported by our outstanding discovery team and multi-dimensional discovery platform. With strong discovery capabilities, we have strategically designed and developed more than 10 oncology-focused projects, including five in the clinical phase. We aspire to be a leading biopharmaceutical company to discover and develop novel differentiated therapies in cancer and other fields to meet the critical unmet needs of patients in China and around the world.
We strategically focus on small molecule precision oncology therapy, small molecule immuno-oncology, and combination therapies. With their good efficacy and safety, we believe this is the development trend and next generation solution for cancer treatment.
CEO： Yaochang Xu
Market： Hong Kong motherboard
Listing Date： 10/13/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet